

-continued

```

<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic
<220> FEATURE:
<221> NAME/KEY: Xaa
<222> LOCATION: (7)..(7)
<223> OTHER INFORMATION: HArg
<220> FEATURE:
<221> NAME/KEY: Xaa
<222> LOCATION: (13)..(13)
<223> OTHER INFORMATION: HyP

```

```

<400> SEQUENCE: 216

```

```

Cys Pro Phe Gly Cys Met Xaa Asp Trp Ser Thr Pro Xaa Trp Cys
1           5           10          15

```

```

<210> SEQ ID NO 217
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic
<220> FEATURE:
<221> NAME/KEY: Xaa
<222> LOCATION: (18)..(18)
<223> OTHER INFORMATION: Sar6-K(F1)

```

```

<400> SEQUENCE: 217

```

```

Ala Cys Pro Phe Gly Cys His Thr Asp Trp Ser Trp Pro Ile Trp Cys
1           5           10          15

```

```

Ala Xaa

```

1. A peptide ligand specific for Nectin-4 comprising a polypeptide comprising at least three cysteine residues, separated by at least two loop sequences, and a molecular scaffold which forms covalent bonds with the cysteine residues of the polypeptide such that at least two polypeptide loops are formed on the molecular scaffold.

2. The peptide ligand as defined in claim 1, wherein said loop sequences comprise 3, 6, 7, 8 or 9 amino acids, such as 3, 6, 7 or 9 amino acids, in particular 3 or 9 amino acids.

3. The peptide ligand as defined in claim 1 or claim 2, wherein said loop sequences comprise three cysteine residues separated by two loop sequences one of which consists of 3 amino acids and the other of which consists of 9 amino acids.

4. The peptide ligand as defined in claim 1 or claim 2, wherein said peptide ligand comprises an amino acid sequence selected from:

```

(CSEQ ID NO: 38)
Ci-P/A/Hyp-F/Y-G/A-Cii-X1-X2-X3-W/1-Nal/2-
```

```

Nal-S/A-X4-P-I/D/A-W/1-Nal/2-Nal-Ciii;

```

```

(CSEQ ID NO: 39)
Ci-W/A-P-L-D/S-S/D-Y-W-Cn-Xs-R-I-Ciii;
```

```

(CSEQ ID NO: 40)
Ci-V-T-T-S-Y-D-Cii-F/W-L/V-H/R/T-L-
```

```

L/G-G/Q/H-Ciii;

```

-continued

```

Ci-X6-X7-X8-Cii-X9-X10-X11-X12- (SEQ ID NO: 41)

```

```

X13-X14-X15-X16-X17-Ciii;
and

```

```

Ci-W/A/Y-P/A-L-D/S/A-S/D/P/A-Y- (SEQ ID NO: 42)

```

```

W/1-Nal-Cii-X5-R/HArg/A-I-Cii;

```

wherein:

X₁-X₅ represent any amino acid residue, including modified and non-natural amino acids;

X₆ represents: Gly; Pro or a non-natural derivative of Pro selected from azetidine (Aze), hydroxyproline (HyP), 4-amino-proline (Pro(4NH)), oxazolidine-4-carboxylic acid (Oxa), octahydroindolecarboxylic acid (Oic) or 4,4-difluoroproline (4,4-DFP); Ala or a non-natural derivative of Ala selected from aminoisobutyric acid (Aib); or Sarcosine (Sar);

X₇ represents: Phe or a non-natural derivative of Phe selected from 3-methyl-phenylalanine (3MePhe), 4-methyl-phenylalanine (4MePhe), homophenylalanine (HPhe), 4,4-biphenylalanine (4,4-BPA) or 3,4-dihydroxy-phenylalanine (DOPA); Tyr; or Ala or a non-natural derivative of Ala selected from 1-naphthylalanine (1-Nal), 2-naphthylalanine (2-Nal) or 2-pyridylalanine (2Pal);

X₈ represents: Gly; Ala; Asp; Lys or a non-natural derivative of Lys selected from acetyl-lysine (KAc or Lys (Ac)); Phe; Glu; Gln; Leu; Ser; Arg; or cysteic acid (Cya);